+

WO2025053239A1 - Agent for improving quality of sleep - Google Patents

Agent for improving quality of sleep Download PDF

Info

Publication number
WO2025053239A1
WO2025053239A1 PCT/JP2024/031944 JP2024031944W WO2025053239A1 WO 2025053239 A1 WO2025053239 A1 WO 2025053239A1 JP 2024031944 W JP2024031944 W JP 2024031944W WO 2025053239 A1 WO2025053239 A1 WO 2025053239A1
Authority
WO
WIPO (PCT)
Prior art keywords
genus
trapa
sleep quality
plant belonging
extract
Prior art date
Application number
PCT/JP2024/031944
Other languages
French (fr)
Japanese (ja)
Inventor
徹 大下
千尋 冨谷
拓人 山▲崎▼
祥子 竹下
Original Assignee
林兼産業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 林兼産業株式会社 filed Critical 林兼産業株式会社
Publication of WO2025053239A1 publication Critical patent/WO2025053239A1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Definitions

  • the present invention relates to a sleep quality improving agent, etc.
  • Patent Document 1 it has been reported that extracts from plants belonging to the Trachyspermum genus have excellent Maillard reaction inhibitory effects (Patent Document 1).
  • Patent Document 2 It has also been reported that compounds isolated from hot water extracts of either or both of the pericarp and fruit of plants belonging to the family Trachycarpa, and having molecular weights in the ranges of 70 to 130 and 290 to 380 as measured by gel filtration chromatography, have a high ability to inhibit the formation of advanced glycation end products (Patent Document 2).
  • Patent Document 3 it has been reported that one or more compounds contained in either or both of the pericarp and fruit of plants belonging to the family Trachycarpa have the activity of improving infertility.
  • the present invention aims to provide an agent that improves sleep quality.
  • the inventors conducted extensive research to achieve the above-mentioned objective, and discovered that a hot water extract of water chestnut peel exhibits a significantly excellent effect in improving sleep quality.
  • the present invention was completed based on these findings and through further investigation, and provides the following sleep quality improving agents, etc.
  • Item 1 Use of a plant belonging to the genus Trapa or a processed product thereof in the manufacture of a sleep quality improving agent.
  • Item 2. The use according to Item 1, wherein the plant belonging to the genus Trapa is Trapa.
  • Item 3. The use according to Item 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of a plant belonging to the genus Trapa.
  • Item 4. The use according to Item 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of the pericarp of a plant belonging to the genus Trapa.
  • Item 1 or 2 wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bisporus pericarp.
  • Item 6 A sleep quality improving agent (or a composition for improving sleep quality) containing a plant belonging to the genus Trapa or a processed product thereof.
  • Item 7. The sleep quality improving agent according to Item 6, wherein the plant belonging to the genus Trapa is Trapa.
  • Item 8 The sleep quality improving agent according to Item 6 or 7, wherein the plant belonging to the genus Trachyspermum or a processed product thereof is an extract of a plant belonging to the genus Trachyspermum.
  • Item 10 The sleep quality improving agent according to Item 6 or 7, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bisporus pericarp.
  • Item 11 A method for improving quality of sleep, comprising the step of administering a plant belonging to the genus Trapa or a processed product thereof to a mammal in need thereof.
  • Item 14 The method according to Item 11 or 12, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of the pericarp of a plant belonging to the genus Trapa.
  • Item 15. The method according to Item 11 or 12, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bispinosa pericarp.
  • Plants belonging to the genus Trapa or processed products thereof have a remarkably excellent effect of improving sleep quality, and are therefore useful as active ingredients in sleep quality improvers.
  • plants belonging to the Trachyspermum genus or processed products thereof are highly safe because they are naturally derived ingredients.
  • the sleep quality improving agent of the present invention is characterized by containing a plant belonging to the genus Trapa or a processed product thereof.
  • Plants belonging to the genus Trapa or processed products thereof Plants belonging to the genus Trapa are not particularly limited, and examples thereof include Trapa japonica, Trapa natans L. ver. Japonica, Trapa incisa, Trapa bispinosa Roxb., Trapa acornis, Trapa natans, etc. Among them, Trapa bispinosa is preferred.
  • a part or the whole of a plant belonging to the genus Trachysperm may be used.
  • parts of a plant include flowers, inflorescences, fruit skin, fruit, flesh, stems, leaves, branches, foliage, trunks, bark, rhizomes, root bark, roots, seeds, galls, heartwood, above-ground parts, and underground parts, and these parts may be used alone or in combination.
  • the term "processed product” is not particularly limited, but may be, for example, a product that has been subjected to some kind of processing on a plant belonging to the genus Trachysus.
  • processed products include extracts, ground products, dried powders, crushed products, squeezed juice, crushed products, heat-treated products, chemically treated products, enzyme-treated products, and combinations thereof.
  • a dried powder of a plant belonging to the genus Trachysus can be produced by drying and further crushing a plant belonging to the genus Trachysus.
  • a plant belonging to the genus Trachysus can be dried by, for example, sun drying, hot air drying, freeze drying, spray drying, etc. Crushing and crushing can be performed, for example, using a crusher, a crusher, etc., respectively.
  • a processed product of a plant belonging to the genus Trachysus is preferably an extract of a plant belonging to the genus Trachysus.
  • an extract of a plant belonging to the genus Trachysperm a part or the whole of the plant belonging to the genus Trachysperm can be used.
  • parts of a plant include flowers, inflorescences, pericarp, fruit, flesh, stems, leaves, branches, foliage, trunks, bark, rhizomes, root bark, roots, seeds, galls, heartwood, above-ground parts, and underground parts, and these can be used alone or in combination of multiple parts.
  • the parts of the plant used to produce the extract are preferably fruits and pericarp, and particularly preferably pericarp.
  • any state of the plant such as raw, dried, cut, or crushed, can be used.
  • the extract of a plant belonging to the genus Trachysperm is preferably an extract of the pericarp of a plant belonging to the genus Trachysperm, and particularly preferably a pericarp extract.
  • the method for producing an extract of a plant belonging to the genus Trapa is not particularly limited, and can be a commonly used method.
  • each part of the plant belonging to the genus Trapa is cut into pieces of appropriate size or whole, and then squeezed or extracted with a solvent.
  • Hot water extraction is particularly preferred as an extraction method.
  • an extraction solvent water, an organic solvent, or a water-containing organic solvent can be used.
  • organic solvent examples include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, and 3-pentanol, ethers such as diethyl ether, esters such as methyl acetate and ethyl acetate, ketones such as acetone, and organic acids such as acetic acid, glacial acetic acid, and propionic acid.
  • lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, and 3-pentanol
  • ethers such as diethyl ether
  • esters such as
  • the extraction solvent is preferably water, methanol, ethanol, or an aqueous solvent obtained by mixing any two or more of these in any ratio, and the particularly preferred extraction solvent is water, or an aqueous solvent obtained by mixing ethanol, an organic solvent approved as a food additive, and water in any ratio.
  • the temperature of the extraction solvent can be any temperature above room temperature and below the boiling point of the extraction solvent, and is desirably determined taking into consideration the extraction efficiency, heat resistance, volatility, etc. of the substance to be extracted. If necessary, a heated extraction solvent can be used to improve the extraction efficiency.
  • the extraction time can be within the range of 1 hour to 15 days.
  • an acid, a base, a salt, etc. can be appropriately contained as necessary to improve the extraction efficiency.
  • There are no particular limitations on the pH of the water used for extraction and it is preferably near neutral in consideration of use on living organisms, more preferably pH 4 to 9, and even more preferably pH 6 to 8.
  • Hot water extraction can be carried out by any known method, for example, a method in which a plant belonging to the genus Trapa is mixed in an extraction solvent for a predetermined time and then separated from the solid matter by filtration, centrifugation, decantation, etc., or a continuous extraction method such as the Soxhlet extraction method can be used.
  • adsorbents and filter aids such as activated carbon, bentonite, celite, etc. can be added to remove impurities as necessary.
  • adsorbents and filter aids such as activated carbon, bentonite, celite, etc.
  • Solvent extracts of plants belonging to the genus Trapa can be used as is, or, if necessary, can be purified by ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography (HPLC), dialysis, or a combination of these.
  • Solvent extracts of plants belonging to the genus Trapa include the recovered extract (including those further purified as necessary), concentrates obtained by concentrating the extract, and solids obtained by removing the solvent from the extract by freeze-drying, spray-drying, etc.
  • concentration, freeze-drying, and spray-drying of the extract can be carried out according to conventional methods.
  • the proportion of a plant belonging to the genus Trachysus or a processed product thereof contained in the sleep quality improving agent of the present invention is not particularly limited and may be, for example, 0.001 to 100% by mass of the total amount of the sleep quality improving agent.
  • the upper or lower limit of the range is, for example, 0.01% by mass, 0.1% by mass, 1% by mass, 5% by mass, 10% by mass, 20% by mass, 30% by mass, 40% by mass, 50% by mass, 60% by mass, 70% by mass, 80% by mass, 90% by mass, 95% by mass, 99% by mass, or 99.9% by mass.
  • improving sleep quality means improving the quality of sleep.
  • Improving sleep quality means improving the quality of sleep.
  • Immprovement means improving or maintaining symptoms or conditions, preventing or delaying the worsening of symptoms or conditions, etc.
  • PSQI Pittsburgh Sleep Quality Index
  • the sleep quality improving agent of the present invention may contain, as appropriate, known ingredients other than plants belonging to the genus Trapa or processed products thereof, as long as the effects of the present invention are not impaired.
  • the sleep quality improving agent of the present invention can be used as food and beverages (particularly (non-therapeutic) food and beverages intended for health, maintenance, or promotion (e.g., health foods, functional foods, nutritional supplements, supplements, foods for specified health uses, foods with nutrient functions, or foods with functional claims)), medicines (including quasi-drugs), etc. Furthermore, the sleep quality improving agent of the present invention also encompasses the meaning of additives that impart an effect of improving sleep quality.
  • extracts of plants belonging to the genus Trapa can be used as is, but if necessary, vitamins, flavonoids, minerals, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, colorants, flavorings, stabilizers, preservatives, disintegrants, lubricants, sustained-release regulators, surfactants, solubilizers, wetting agents, etc. can also be added.
  • Food and drink includes all foods and drink that can be consumed by animals (including humans).
  • types of food and drink include dairy products; fermented foods (yogurt, cheese, etc.); beverages (soft drinks such as coffee, juice, and tea drinks, dairy drinks, lactic acid bacteria drinks, drinks containing lactic acid bacteria, yogurt drinks, carbonated drinks, sake, Western liquor, and alcohol such as fruit wine); spreads (custard cream, etc.); pastes (fruit paste, etc.); Western sweets (chocolate, donuts, pies, cream puffs, gum, candy, jelly, cookies, cakes, puddings, etc.); Japanese sweets (daifuku, mochi, manju, castella, anmitsu, yokan, etc.); frozen desserts (ice cream, popsicles, sorbet, etc.); foods (curry, beef bowl, porridge, miso soup, soup, meat sauce, pasta, pickles, jam, etc.); and seasonings (dressing, furikake, umami seasonings
  • the method for producing the food and beverages is not particularly limited, and any known method can be used as appropriate.
  • the dosage unit form is not particularly limited and can be selected appropriately, and examples include tablets, capsules, granules, liquids, powders, etc.
  • the amount of food and drink to be consumed can be set appropriately depending on various conditions such as the consumer's weight, age, sex, symptoms, etc.
  • the above medicines can use only plants belonging to the genus Trapa or processed products thereof, or they can be mixed with other medicinal ingredients listed in the Japanese Pharmacopoeia, such as vitamins and herbal medicines.
  • plants belonging to the genus Trapa or processed products thereof can be used as is, or can be prepared together with pharmaceutical acceptable ingredients into pharmaceutical preparations in the form of tablets (including plain tablets, sugar-coated tablets, film-coated tablets, effervescent tablets, chewable tablets, troches, etc.), capsules, pills, powders (dispersed medicines), fine granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including cases where they are mixed with distilled water or infusions such as amino acid infusions or electrolyte infusions at the time of use to prepare them as liquids), etc.
  • tablets including plain tablets, sugar-coated tablets, film-coated tablets, effervescent tablets, chewable tablets, troches, etc.
  • capsules pills, powders (dispersed medicines), fine granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including cases where they are mixed with distilled
  • pharmaceuticals may contain pharma- ceutical acceptable ingredients such as excipients, binders, disintegrants, lubricants, suspending agents, thickeners, antioxidants, absorption promoters, pH regulators, colorants, preservatives, surfactants, stabilizers, sweeteners, flavorings, and fragrances, as necessary.
  • pharma- ceutical acceptable ingredients such as excipients, binders, disintegrants, lubricants, suspending agents, thickeners, antioxidants, absorption promoters, pH regulators, colorants, preservatives, surfactants, stabilizers, sweeteners, flavorings, and fragrances, as necessary.
  • the method of administration of the pharmaceutical is not particularly limited, and can be, for example, oral administration, intra-arterial administration, intravenous administration, buccal administration, rectal administration, enteral administration, transdermal administration, etc.
  • the dosage of a pharmaceutical product can be determined appropriately depending on various conditions such as the patient's weight, age, sex, symptoms, administration method, and type of dosage form.
  • the dosage and intake of foods, beverages, and medicines for humans is generally the amount of active ingredient contained in the formulation, and is preferably 0.1 to 2000 mg/day per adult.
  • the dosage and intake will vary depending on various conditions, so there are cases where a smaller dosage and intake than the above is sufficient, and cases where a greater amount than the above range is required.
  • the sleep quality improving agent of the present invention described above is applicable to mammals, including humans.
  • the sleep quality improving agent of the present invention is effective for people who wake up during sleep, feel sleepy during the day, and have light sleep.
  • the sleep quality improving agent of the present invention When used as a food or beverage, it may be labeled as "It has been reported to have the function of improving sleep quality" or a similar labeling may be used.
  • plants belonging to the genus Trapa or processed products thereof have an excellent effect of improving sleep quality. Therefore, since plants belonging to the genus Trapa or processed products thereof have an excellent effect of improving sleep quality, they can be suitably used as an active ingredient in sleep quality improvers.
  • plants belonging to the Trachyspermum genus or processed products thereof are highly safe because they are naturally derived ingredients.
  • the term “comprising” includes “consisting essentially of” and “consisting of.”
  • the present invention includes any combination of the constituent elements described in this specification.
  • test food was prepared as a capsule (total mass 234 mg) containing 100 mg of water chestnut peel extract powder, 83.62 mg of corn starch as excipients, and 1.38 mg of calcium stearate encapsulated in 49 mg of hard capsules.
  • intervention period was 8 weeks, and participants were instructed to take one tablet of the test food or placebo food per day before breakfast with water or lukewarm water.
  • the placebo food used an excipient that did not contain water chestnut extract, and was indistinguishable in appearance, shape, color, odor, and taste.
  • the Pittsburgh Sleep Quality Index allows for self-reporting, scoring and evaluation of overall sleep quality, and is the sleep scale with the most accumulated evidence among existing sleep scales.
  • the Pittsburgh Sleep Quality Index is composed of seven subscales, including sleep quality, time to fall asleep, sleep duration, sleep efficiency, difficulty sleeping, use of sleeping pills and daytime activity disorders, and is evaluated based on the total score of these subscales.
  • Study results [Subjects for analysis of intergroup comparison] Of the 56 subjects enrolled in the study (28 in the test food group and 28 in the placebo group), one subject (test food group) did not visit the hospital for the measurement at week 4 only, one subject (test food group) did not visit the hospital for the measurement at week 8 only, and one subject (placebo group) did not visit the hospital for either the measurement at week 4 or week 8. Therefore, in the test food group, 28 subjects were included in the total number of subjects for analysis, including subjects with missing data at either week 4 or week 8, and 27 subjects each were included in the data for analysis, excluding one subject each who did not visit the hospital at week 4 or week 8. In the placebo group, 27 subjects were included in the analysis, excluding one subject for whom measurement data could not be obtained at weeks 4 and 8, and an intergroup comparison analysis was performed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Botany (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Disclosed is the use of a plant belonging to the genus Trapa or a processed product thereof in the production of an agent for improving the quality of sleep.

Description

睡眠の質改善剤Sleep quality improver

 本発明は、睡眠の質改善剤等に関する。 The present invention relates to a sleep quality improving agent, etc.

 人間は人生の約3分の1を「睡眠」に費やしており、睡眠は人間にとって最も重要な行為と考えられる。しかしながら、現代人の睡眠は、様々な外部環境要因により質及び量ともに低下しており、睡眠不足及び不眠の症状を訴える人が多く存在する。睡眠の質の低下は、心筋梗塞、脳梗塞等の重体な疾患につながるだけで無く、集中力及び労働パフォーマンスにも影響することから、より優れた睡眠改善効果を有する商品が望まれる。 Humans spend about one-third of their lives sleeping, and sleep is considered to be the most important human activity. However, the quality and quantity of sleep that modern people get is declining due to various external environmental factors, and many people complain of symptoms of sleep deprivation and insomnia. A decline in sleep quality not only leads to serious illnesses such as myocardial infarction and cerebral infarction, but also affects concentration and work performance, so there is a demand for products that have a more effective effect on improving sleep.

 一方で、ヒシ属に属する植物のエキスが優れたメイラード反応阻害作用を有することが報告されている(特許文献1)。 On the other hand, it has been reported that extracts from plants belonging to the Trachyspermum genus have excellent Maillard reaction inhibitory effects (Patent Document 1).

 また、ヒシ科に属する植物の果皮及び果実の一方又は双方の熱水抽出物より分離される化合物であって、ゲルろ過クロマトグラフィーにより測定された分子量が70~130及び290~380の範囲内にある化合物が、高い終末糖化産物生成阻害能を有することが報告されている(特許文献2)。 It has also been reported that compounds isolated from hot water extracts of either or both of the pericarp and fruit of plants belonging to the family Trachycarpa, and having molecular weights in the ranges of 70 to 130 and 290 to 380 as measured by gel filtration chromatography, have a high ability to inhibit the formation of advanced glycation end products (Patent Document 2).

 さらに、ヒシ科に属する植物の果皮及び果実の一方又は双方に含まれる1又は複数の化合物が、不妊の改善活性を有することも報告されている(特許文献3)。 Furthermore, it has been reported that one or more compounds contained in either or both of the pericarp and fruit of plants belonging to the family Trachycarpa have the activity of improving infertility (Patent Document 3).

 その他、ヒシ科に属する植物の果皮及び果実の一方又は双方に含まれる1又は複数の化合物が、高いアディポネクチン分泌促進活性及び脂肪前駆細胞分化促進活性を有することも報告されている(特許文献4)。 It has also been reported that one or more compounds contained in either or both of the pericarp and fruit of plants belonging to the family Trachycarpa have high adiponectin secretion promoting activity and adipose precursor cell differentiation promoting activity (Patent Document 4).

 ヒシ科に属する植物の果皮及び果実の一方又は双方に含まれる1又は複数の化合物が、高いアミロイドβ凝集阻害活性、及びBACE1阻害活性を有しており、抗アルツハイマー組成物の成分とすることが報告されている(特許文献5)。 It has been reported that one or more compounds contained in either or both of the pericarp and fruit of plants belonging to the family Trachycarpa have high amyloid-β aggregation inhibitory activity and BACE1 inhibitory activity, and can be used as a component of an anti-Alzheimer's composition (Patent Document 5).

日本国特開2014-94964号公報Japanese Patent Application Publication No. 2014-94964 日本国特開2015-209420号公報Japanese Patent Application Publication No. 2015-209420 日本国特開2016-145182号公報Japanese Patent Application Publication No. 2016-145182 日本国特開2019-52122号公報Japanese Patent Application Publication No. 2019-52122 日本国特開2020-83815号公報Japanese Patent Application Publication No. 2020-83815

 このように、ヒシ属に属する植物のエキスが各種の効果を有することは知られているが、ヒシ属に属する植物のエキスが、睡眠の質の改善作用などを有することは知られていない。 As such, it is known that extracts of plants belonging to the Trachyspermum genus have various effects, but it is not known that extracts of plants belonging to the Trachyspermum genus have the effect of improving sleep quality, etc.

 本発明は、睡眠の質改善剤を提供することを目的とする。 The present invention aims to provide an agent that improves sleep quality.

 本発明者らは、上記目的を達成すべく鋭意研究を重ねた結果、トウビシ果皮の熱水抽出物が、顕著に優れた睡眠の質の改善効果を示すという知見を得た。 The inventors conducted extensive research to achieve the above-mentioned objective, and discovered that a hot water extract of water chestnut peel exhibits a significantly excellent effect in improving sleep quality.

 本発明は、これら知見に基づき、更に検討を重ねて完成されたものであり、次の睡眠の質改善剤等を提供するものである。 The present invention was completed based on these findings and through further investigation, and provides the following sleep quality improving agents, etc.

項1.睡眠の質改善剤の製造における、ヒシ属に属する植物又はその処理物の使用。
項2.前記ヒシ属に属する植物がトウビシである、項1に記載の使用。
項3.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の抽出物である、項1又は2に記載の使用。
項4.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の果皮の抽出物である、項1又は2に記載の使用。
項5.前記ヒシ属に属する植物又はその処理物が、トウビシ果皮抽出物である、項1又は2に記載の使用。
項6.ヒシ属に属する植物又はその処理物を含有する睡眠の質改善剤(又は睡眠の質改善用組成物)。
項7.前記ヒシ属に属する植物がトウビシである、項6に記載の睡眠の質改善剤。
項8.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の抽出物である、項6又は7に記載の睡眠の質改善剤。
項9.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の果皮の抽出物である、項6又は7に記載の睡眠の質改善剤。
項10.前記ヒシ属に属する植物又はその処理物が、トウビシ果皮抽出物である、項6又は7に記載の睡眠の質改善剤。
項11.睡眠の質を改善する方法であって、ヒシ属に属する植物又はその処理物を、それを必要とする哺乳動物に投与する工程を含む、方法。
項12.前記ヒシ属に属する植物がトウビシである、項11に記載の方法。
項13.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の抽出物である、項11又は12に記載の方法。
項14.前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の果皮の抽出物である、項11又は12に記載の方法。
項15.前記ヒシ属に属する植物又はその処理物が、トウビシ果皮抽出物である、項11又は12に記載の方法。
Item 1. Use of a plant belonging to the genus Trapa or a processed product thereof in the manufacture of a sleep quality improving agent.
Item 2. The use according to Item 1, wherein the plant belonging to the genus Trapa is Trapa.
Item 3. The use according to Item 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of a plant belonging to the genus Trapa.
Item 4. The use according to Item 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of the pericarp of a plant belonging to the genus Trapa.
Item 5. The use according to Item 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bisporus pericarp.
Item 6. A sleep quality improving agent (or a composition for improving sleep quality) containing a plant belonging to the genus Trapa or a processed product thereof.
Item 7. The sleep quality improving agent according to Item 6, wherein the plant belonging to the genus Trapa is Trapa.
Item 8. The sleep quality improving agent according to Item 6 or 7, wherein the plant belonging to the genus Trachyspermum or a processed product thereof is an extract of a plant belonging to the genus Trachyspermum.
Item 9. The sleep quality improving agent according to Item 6 or 7, wherein the plant belonging to the Trachys genus or a processed product thereof is an extract of the pericarp of a plant belonging to the Trachys genus.
Item 10. The sleep quality improving agent according to Item 6 or 7, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bisporus pericarp.
Item 11. A method for improving quality of sleep, comprising the step of administering a plant belonging to the genus Trapa or a processed product thereof to a mammal in need thereof.
Item 12. The method according to Item 11, wherein the plant belonging to the genus Trapa is Trapa.
Item 13. The method according to Item 11 or 12, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of a plant belonging to the genus Trapa.
Item 14. The method according to Item 11 or 12, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of the pericarp of a plant belonging to the genus Trapa.
Item 15. The method according to Item 11 or 12, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bispinosa pericarp.

 ヒシ属に属する植物又はその処理物は、顕著に優れた睡眠の質の改善作用を有するので、睡眠の質改善剤の有効成分として有用である。 Plants belonging to the genus Trapa or processed products thereof have a remarkably excellent effect of improving sleep quality, and are therefore useful as active ingredients in sleep quality improvers.

 また、ヒシ属に属する植物又はその処理物は、天然由来成分であるので安全性が高い。 In addition, plants belonging to the Trachyspermum genus or processed products thereof are highly safe because they are naturally derived ingredients.

実施例のピッツバーグ睡眠質問票の日中覚醒困難のスコアの結果を示すグラフである。左:日中覚醒困難のスコア(EMM(推定周辺平均))、p値はANCOVAに基づく、右:日中覚醒困難のスコア推移(Mean(平均値))Graph showing the results of the daytime wakefulness score of the Pittsburgh Sleep Quality Index in an embodiment. Left: Daytime wakefulness score (EMM (Estimated Marginal Mean)), p value based on ANCOVA, Right: Daytime wakefulness score change (Mean)

 以下、本発明の実施の形態について詳細に説明する。 The following is a detailed explanation of an embodiment of the present invention.

 本発明の睡眠の質改善剤は、ヒシ属に属する植物又はその処理物を含有することを特徴とする。 The sleep quality improving agent of the present invention is characterized by containing a plant belonging to the genus Trapa or a processed product thereof.

 ヒシ属に属する植物又はその処理物
 ヒシ属に属する植物としては、特に制限されず、例えば、ヒシ(Trapa japonica)、オニビシ(Trapa natans L.ver.Japonica)、ヒメビシ(Trapa incisa)、トウビシ(Trapa bispinosa Roxb.)、ツノナシビシ(Trapa acornis)、トラパ・ナタンス(Trapa natans)などが挙げられる。中でも、トウビシが好ましい。
Plants belonging to the genus Trapa or processed products thereof Plants belonging to the genus Trapa are not particularly limited, and examples thereof include Trapa japonica, Trapa natans L. ver. Japonica, Trapa incisa, Trapa bispinosa Roxb., Trapa acornis, Trapa natans, etc. Among them, Trapa bispinosa is preferred.

 ヒシ属に属する植物としては、ヒシ属に属する植物の一部若しくは全体を使用することもできる。植物の一部としては、花、花穂、果皮、果実、果肉、茎、葉、枝、枝葉、幹、樹皮、根茎、根皮、根、種子、虫えい、心材、地上部、地下部などが挙げられ、これらを単独又は複数部位を組み合わせて使用することができる。 As the plant belonging to the genus Trachysperm, a part or the whole of a plant belonging to the genus Trachysperm may be used. Examples of parts of a plant include flowers, inflorescences, fruit skin, fruit, flesh, stems, leaves, branches, foliage, trunks, bark, rhizomes, root bark, roots, seeds, galls, heartwood, above-ground parts, and underground parts, and these parts may be used alone or in combination.

 本発明において、「処理物」とは特に限定はないが、例えば、ヒシ属に属する植物に対し何らかの加工を施したものであればよい。処理物としては、例えば、抽出物、磨砕物、乾燥粉末、粉砕物、搾汁液、破砕物、加熱処理物、化学処理物、酵素処理物、これらの組み合わせなどが挙げられる。ヒシ属に属する植物の乾燥粉末は、ヒシ属に属する植物を乾燥し、更に粉砕することにより作製することができる。ヒシ属に属する植物の乾燥は、例えば、天日乾燥、熱風乾燥、凍結乾燥、噴霧乾燥等によって行うことができる。粉砕及び破砕は、例えば、それぞれ粉砕機、破砕機等を用いて行うことができる。ヒシ属に属する植物の処理物としては、好ましくはヒシ属に属する植物の抽出物である。 In the present invention, the term "processed product" is not particularly limited, but may be, for example, a product that has been subjected to some kind of processing on a plant belonging to the genus Trachysus. Examples of processed products include extracts, ground products, dried powders, crushed products, squeezed juice, crushed products, heat-treated products, chemically treated products, enzyme-treated products, and combinations thereof. A dried powder of a plant belonging to the genus Trachysus can be produced by drying and further crushing a plant belonging to the genus Trachysus. A plant belonging to the genus Trachysus can be dried by, for example, sun drying, hot air drying, freeze drying, spray drying, etc. Crushing and crushing can be performed, for example, using a crusher, a crusher, etc., respectively. A processed product of a plant belonging to the genus Trachysus is preferably an extract of a plant belonging to the genus Trachysus.

 ヒシ属に属する植物の抽出物の製造には、ヒシ属に属する植物の一部若しくは全体を使用することもできる。植物の一部としては、花、花穂、果皮、果実、果肉、茎、葉、枝、枝葉、幹、樹皮、根茎、根皮、根、種子、虫えい、心材、地上部、地下部などが挙げられ、これらを単独又は複数部位を組み合わせて使用することができる。抽出物の製造に使用する植物の部位としては、好ましくは果実及び果皮、特に好ましくは果皮である。また、抽出物の製造には、生の物、乾燥した物、切断又は粉砕された物などいずれの状態の植物も使用することができる。ヒシ属に属する植物の抽出物としては、好ましくはヒシ属に属する植物の果皮の抽出物であり、特に好ましくはトウビシ果皮抽出物である。 To produce an extract of a plant belonging to the genus Trachysperm, a part or the whole of the plant belonging to the genus Trachysperm can be used. Examples of parts of a plant include flowers, inflorescences, pericarp, fruit, flesh, stems, leaves, branches, foliage, trunks, bark, rhizomes, root bark, roots, seeds, galls, heartwood, above-ground parts, and underground parts, and these can be used alone or in combination of multiple parts. The parts of the plant used to produce the extract are preferably fruits and pericarp, and particularly preferably pericarp. In addition, to produce the extract, any state of the plant, such as raw, dried, cut, or crushed, can be used. The extract of a plant belonging to the genus Trachysperm is preferably an extract of the pericarp of a plant belonging to the genus Trachysperm, and particularly preferably a pericarp extract.

 ヒシ属に属する植物の抽出物を製造する方法としては、特に制限されず、通常用いられる方法により行うことができる。そのような方法としては、例えば、ヒシ属に属する植物の各部位をそのまま又は適当な大きさに切断し、搾汁又は溶媒で抽出することにより行うことが挙げられる。抽出方法としては、熱水抽出が特に好ましい。そのような抽出溶媒としては水、有機溶媒又は含水有機溶媒を使用することができ、有機溶媒としては、例えば、メタノール、エタノール、1-プロパノール、2-プロパノール、1-ブタノール、2-ブタノール、2-メチル-1-プロパノール、2-メチル-2-プロパノール、1-ペンタノール、2-ペンタノール、3-ペンタノール等の炭素数1~5の低級アルコール、ジエチルエーテル等のエーテル類、酢酸メチル、酢酸エチル等のエステル類、アセトン等のケトン類、酢酸、氷酢酸、プロピオン酸等の有機酸等が挙げられる。抽出溶媒としては、好ましくは、水、メタノール、エタノール及びこれらの任意の2種以上を任意の割合で混合した水性溶媒であり、特に好ましい抽出溶媒は、水、食品添加物として認められている有機溶媒であるエタノールと水とを任意の割合で混合した水性溶媒である。 The method for producing an extract of a plant belonging to the genus Trapa is not particularly limited, and can be a commonly used method. For example, each part of the plant belonging to the genus Trapa is cut into pieces of appropriate size or whole, and then squeezed or extracted with a solvent. Hot water extraction is particularly preferred as an extraction method. As such an extraction solvent, water, an organic solvent, or a water-containing organic solvent can be used. Examples of the organic solvent include lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, and 3-pentanol, ethers such as diethyl ether, esters such as methyl acetate and ethyl acetate, ketones such as acetone, and organic acids such as acetic acid, glacial acetic acid, and propionic acid. The extraction solvent is preferably water, methanol, ethanol, or an aqueous solvent obtained by mixing any two or more of these in any ratio, and the particularly preferred extraction solvent is water, or an aqueous solvent obtained by mixing ethanol, an organic solvent approved as a food additive, and water in any ratio.

 抽出溶媒の温度は、室温を超え抽出溶媒の沸点以下の任意の温度とすることができ、抽出効率、被抽出物の耐熱性、揮発性等を考慮して決定されることが望ましい。必要に応じて、抽出効率を向上させるために、加熱した抽出溶媒を用いることもできる。抽出時間としては、1時間~15日の範囲内が挙げられる。抽出溶媒として水及び水性溶媒を用いる場合には、抽出効率を向上させるために、必要に応じて、酸、塩基、塩等を適宜含ませることができる。抽出に用いる水のpHとしては、特に制限されず、生体への使用を考慮して中性付近が好ましく、pH4~9がより好ましく、pH6~8が更に好ましい。 The temperature of the extraction solvent can be any temperature above room temperature and below the boiling point of the extraction solvent, and is desirably determined taking into consideration the extraction efficiency, heat resistance, volatility, etc. of the substance to be extracted. If necessary, a heated extraction solvent can be used to improve the extraction efficiency. The extraction time can be within the range of 1 hour to 15 days. When water or an aqueous solvent is used as the extraction solvent, an acid, a base, a salt, etc. can be appropriately contained as necessary to improve the extraction efficiency. There are no particular limitations on the pH of the water used for extraction, and it is preferably near neutral in consideration of use on living organisms, more preferably pH 4 to 9, and even more preferably pH 6 to 8.

 熱水抽出は任意の公知の方法により行うことができ、例えば、ヒシ属に属する植物を抽出溶媒中で所定時間混合後、ろ過、遠心分離、デカンテーション等により固形分と分離する方法、ソックスレー抽出法等の連続抽出法等の方法を用いることができる。 Hot water extraction can be carried out by any known method, for example, a method in which a plant belonging to the genus Trapa is mixed in an extraction solvent for a predetermined time and then separated from the solid matter by filtration, centrifugation, decantation, etc., or a continuous extraction method such as the Soxhlet extraction method can be used.

 ろ過により不溶分等を除去する場合には、必要に応じて、不純物を除去するために活性炭、ベントナイト、セライト等の吸着剤及びろ過助剤を添加することもできる。特に抽出液の状態で用いる場合には、メンブレンフィルター等による除菌ろ過を併せて行うことが好ましい。 When removing insoluble matter by filtration, adsorbents and filter aids such as activated carbon, bentonite, celite, etc. can be added to remove impurities as necessary. In particular, when using the extract in the form of a liquid, it is preferable to also perform sterilization filtration using a membrane filter, etc.

 ヒシ属に属する植物の溶媒抽出物は、そのままでも使用することができ、必要に応じて、限外濾過、分子篩クロマトグラフィー(ゲル濾過)、吸着クロマトグラフィー、イオン交換クロマトグラフィー、アフィニティクロマトグラフィー、高速液体クロマトグラフィー(HPLC)、透析法、これらの組合せなどによる精製を行うことができる。  Solvent extracts of plants belonging to the genus Trapa can be used as is, or, if necessary, can be purified by ultrafiltration, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography, high performance liquid chromatography (HPLC), dialysis, or a combination of these.

 ヒシ属に属する植物の溶媒抽出物としては、回収された抽出液(必要に応じて更に精製されたものも含む)、当該抽出液を濃縮した濃縮液、凍結乾燥、スプレードライ等により当該抽出液の溶媒が除去された固形物などが含まれる。ここで、抽出液の濃縮、凍結乾燥及びスプレードライは、常法に従って行うことができる。 Solvent extracts of plants belonging to the genus Trapa include the recovered extract (including those further purified as necessary), concentrates obtained by concentrating the extract, and solids obtained by removing the solvent from the extract by freeze-drying, spray-drying, etc. Here, the concentration, freeze-drying, and spray-drying of the extract can be carried out according to conventional methods.

 睡眠の質改善剤
 本発明の睡眠の質改善剤に含まれるヒシ属に属する植物又はその処理物の割合は、特に制限されず、例えば、睡眠の質改善剤全量中0.001~100質量%であり得る。当該範囲の上限又は下限は、例えば、0.01質量%、0.1質量%、1質量%、5質量%、10質量%、20質量%、30質量%、40質量%、50質量%、60質量%、70質量%、80質量%、90質量%、95質量%、99質量%、99.9質量%である。
Sleep quality improving agent The proportion of a plant belonging to the genus Trachysus or a processed product thereof contained in the sleep quality improving agent of the present invention is not particularly limited and may be, for example, 0.001 to 100% by mass of the total amount of the sleep quality improving agent. The upper or lower limit of the range is, for example, 0.01% by mass, 0.1% by mass, 1% by mass, 5% by mass, 10% by mass, 20% by mass, 30% by mass, 40% by mass, 50% by mass, 60% by mass, 70% by mass, 80% by mass, 90% by mass, 95% by mass, 99% by mass, or 99.9% by mass.

 本発明において「睡眠の質の改善」とは、睡眠を質的に改善することを意味する。「改善」とは、症状又は状態の好転又は維持、症状又は状態の悪化の防止又は遅延などを意味する。 In the present invention, "improving sleep quality" means improving the quality of sleep. "Improvement" means improving or maintaining symptoms or conditions, preventing or delaying the worsening of symptoms or conditions, etc.

 睡眠の質を評価する手法としては、例えば、ピッツバーグ睡眠質問票(PSQI)を用いて評価する方法が挙げられる。 One method for assessing sleep quality is, for example, the Pittsburgh Sleep Quality Index (PSQI).

 本発明の睡眠の質改善剤には、本発明の効果を妨げない範囲で、ヒシ属に属する植物又はその処理物以外の公知の成分を適宜配合することができる。  The sleep quality improving agent of the present invention may contain, as appropriate, known ingredients other than plants belonging to the genus Trapa or processed products thereof, as long as the effects of the present invention are not impaired.

 本発明の睡眠の質改善剤は、飲食品(特に、(非治療用途であって)保健、健康維持、増進等を目的とする飲食品(例えば、健康食品、機能性食品、栄養補助食品、サプリメント、特定保健用食品、栄養機能食品、又は機能性表示食品))、医薬品(医薬部外品も含む)などとして使用することができる。また、本発明の睡眠の質改善剤は、それぞれ睡眠の質改善作用を付与する添加剤についての意味も包含するものである。 The sleep quality improving agent of the present invention can be used as food and beverages (particularly (non-therapeutic) food and beverages intended for health, maintenance, or promotion (e.g., health foods, functional foods, nutritional supplements, supplements, foods for specified health uses, foods with nutrient functions, or foods with functional claims)), medicines (including quasi-drugs), etc. Furthermore, the sleep quality improving agent of the present invention also encompasses the meaning of additives that impart an effect of improving sleep quality.

 上記の飲食品には、ヒシ属に属する植物の抽出物をそのまま使用することもできるが、必要に応じて、ビタミン類、フラボノイド類、ミネラル類、キノン類、ポリフェノール類、アミノ酸、核酸、必須脂肪酸、清涼剤、結合剤、甘味料、着色料、香料、安定化剤、防腐剤、崩壊剤、滑沢剤、徐放調整剤、界面活性剤、溶解剤、湿潤剤等を配合することができる。  In the above-mentioned foods and beverages, extracts of plants belonging to the genus Trapa can be used as is, but if necessary, vitamins, flavonoids, minerals, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, colorants, flavorings, stabilizers, preservatives, disintegrants, lubricants, sustained-release regulators, surfactants, solubilizers, wetting agents, etc. can also be added.

 飲食品には、動物(ヒトを含む)が摂取できるあらゆる飲食品が含まれる。飲食品の種類は、特に限定されず、例えば、乳製品;発酵食品(ヨーグルト、チーズ等);飲料類(コーヒー、ジュース、茶飲料のような清涼飲料、乳飲料、乳酸菌飲料、乳酸菌入り飲料、ヨーグルト飲料、炭酸飲料、日本酒、洋酒、果実酒のような酒等);スプレッド類(カスタードクリーム等);ペースト類(フルーツペースト等);洋菓子類(チョコレート、ドーナツ、パイ、シュークリーム、ガム、キャンデー、ゼリー、クッキー、ケーキ、プリン等);和菓子類(大福、餅、饅頭、カステラ、あんみつ、羊羹等);氷菓類(アイスクリーム、アイスキャンデー、シャーベット等);食品類(カレー、牛丼、雑炊、味噌汁、スープ、ミートソース、パスタ、漬物、ジャム等);調味料類(ドレッシング、ふりかけ、旨味調味料、スープの素等)などが挙げられる。 Food and drink includes all foods and drink that can be consumed by animals (including humans). There are no particular limitations on the types of food and drink, and examples include dairy products; fermented foods (yogurt, cheese, etc.); beverages (soft drinks such as coffee, juice, and tea drinks, dairy drinks, lactic acid bacteria drinks, drinks containing lactic acid bacteria, yogurt drinks, carbonated drinks, sake, Western liquor, and alcohol such as fruit wine); spreads (custard cream, etc.); pastes (fruit paste, etc.); Western sweets (chocolate, donuts, pies, cream puffs, gum, candy, jelly, cookies, cakes, puddings, etc.); Japanese sweets (daifuku, mochi, manju, castella, anmitsu, yokan, etc.); frozen desserts (ice cream, popsicles, sorbet, etc.); foods (curry, beef bowl, porridge, miso soup, soup, meat sauce, pasta, pickles, jam, etc.); and seasonings (dressing, furikake, umami seasonings, soup bases, etc.).

 飲食品の製法も特に限定されず、適宜公知の方法に従うことができる。 The method for producing the food and beverages is not particularly limited, and any known method can be used as appropriate.

 飲食品をサプリメントとして使用する際の投与単位形態については特に限定されず適宜選択でき、例えば、錠剤、カプセル剤、顆粒剤、液剤、散剤等が挙げられる。 When using foods and beverages as supplements, the dosage unit form is not particularly limited and can be selected appropriately, and examples include tablets, capsules, granules, liquids, powders, etc.

 飲食品の摂取量は、摂取者の体重、年齢、性別、症状などの種々の条件に応じて適宜設定することができる。 The amount of food and drink to be consumed can be set appropriately depending on various conditions such as the consumer's weight, age, sex, symptoms, etc.

 上記の医薬品には、ヒシ属に属する植物又はその処理物のみを使用することもでき、ビタミン、生薬など日本薬局方に記載の他の医薬成分と混合して使用することもできる。 The above medicines can use only plants belonging to the genus Trapa or processed products thereof, or they can be mixed with other medicinal ingredients listed in the Japanese Pharmacopoeia, such as vitamins and herbal medicines.

 医薬品として調製する場合、ヒシ属に属する植物又はその処理物をそのまま使用するか、又は医薬品において許容される成分とともに、タブレット(素錠、糖衣錠、フィルムコート錠、発泡錠、チュアブル錠、トローチ剤などを含む)、カプセル剤、丸剤、粉末剤(散剤)、細粒剤、顆粒剤、液剤、懸濁液、乳濁液、シロップ、ペースト、注射剤(使用時に、蒸留水又はアミノ酸輸液、電解質輸液等の輸液に配合して液剤として調製する場合を含む)などの形態に調製して、医薬用の製剤にすることが可能である。 When prepared as a medicine, plants belonging to the genus Trapa or processed products thereof can be used as is, or can be prepared together with pharmaceutical acceptable ingredients into pharmaceutical preparations in the form of tablets (including plain tablets, sugar-coated tablets, film-coated tablets, effervescent tablets, chewable tablets, troches, etc.), capsules, pills, powders (dispersed medicines), fine granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including cases where they are mixed with distilled water or infusions such as amino acid infusions or electrolyte infusions at the time of use to prepare them as liquids), etc.

 医薬品には、ヒシ属に属する植物又はその処理物以外にも、必要に応じて、賦形剤、結合剤、崩壊剤、滑沢剤、懸濁化剤、増粘剤、抗酸化剤、吸収促進剤、pH調節剤、着色剤、保存剤、防腐剤、界面活性剤、安定化剤、甘味剤、矯味剤、香料等の薬学的に許容される成分を適宜配合することができる。 In addition to plants belonging to the genus Trapa or processed products thereof, pharmaceuticals may contain pharma- ceutical acceptable ingredients such as excipients, binders, disintegrants, lubricants, suspending agents, thickeners, antioxidants, absorption promoters, pH regulators, colorants, preservatives, surfactants, stabilizers, sweeteners, flavorings, and fragrances, as necessary.

 医薬品の投与方法は特に限定されず、例えば、経口投与、動脈内投与、静脈内投与、口腔内投与、直腸投与、経腸投与、経皮投与などにより行うことができる。 The method of administration of the pharmaceutical is not particularly limited, and can be, for example, oral administration, intra-arterial administration, intravenous administration, buccal administration, rectal administration, enteral administration, transdermal administration, etc.

 医薬品の投与量は、患者の体重、年齢、性別、症状、投与方法、剤型の種類などの種々の条件に応じて適宜決定することができる。 The dosage of a pharmaceutical product can be determined appropriately depending on various conditions such as the patient's weight, age, sex, symptoms, administration method, and type of dosage form.

 飲食品及び医薬品の投与量及び摂取量としては、ヒトの場合、一般には製剤中に含有される有効成分の量で、好ましくは成人1日当り0.1~2000mg/日である。もちろん投与量及び摂取量は、種々の条件によって変動するので、上記投与量及び摂取量より少ない量で十分な場合もあるし、或いは上記範囲を超えて必要な場合もある。 The dosage and intake of foods, beverages, and medicines for humans is generally the amount of active ingredient contained in the formulation, and is preferably 0.1 to 2000 mg/day per adult. Of course, the dosage and intake will vary depending on various conditions, so there are cases where a smaller dosage and intake than the above is sufficient, and cases where a greater amount than the above range is required.

 以上説明した本発明の睡眠の質改善剤は、ヒトを含む哺乳動物に対して適用されるものである。 The sleep quality improving agent of the present invention described above is applicable to mammals, including humans.

 本発明の睡眠の質改善剤は、睡眠の途中で目が覚めてしまうヒト、日中眠さを感じるヒト、眠りが浅いヒトなどに対して有効である。 The sleep quality improving agent of the present invention is effective for people who wake up during sleep, feel sleepy during the day, and have light sleep.

 本発明の睡眠の質改善剤を飲食品として使用する場合、「睡眠の質を向上させる機能があると報告されています。」と表示してもよく、又はこれに類似する表示を行ってもよい。 When the sleep quality improving agent of the present invention is used as a food or beverage, it may be labeled as "It has been reported to have the function of improving sleep quality" or a similar labeling may be used.

 後述する実施例で示すように、本発明者らは、ヒシ属に属する植物又はその処理物が優れた睡眠の質改善作用を示すことを見出した。そのため、ヒシ属に属する植物又はその処理物は、優れた睡眠の質改善作用を有するので、睡眠の質改善剤の有効成分として好適に使用することができる。 As shown in the examples below, the inventors have found that plants belonging to the genus Trapa or processed products thereof have an excellent effect of improving sleep quality. Therefore, since plants belonging to the genus Trapa or processed products thereof have an excellent effect of improving sleep quality, they can be suitably used as an active ingredient in sleep quality improvers.

 また、ヒシ属に属する植物又はその処理物は、天然由来成分であるので安全性が高い。 In addition, plants belonging to the Trachyspermum genus or processed products thereof are highly safe because they are naturally derived ingredients.

 なお、本明細書において「含む」とは、「本質的にからなる」と、「からなる」をも包含する(The term “comprising” includes “consisting essentially of” and “consisting of.”)。また、本発明は、本明細書に説明した構成要件を任意の組み合わせを全て包含する。 In this specification, the term "comprising" includes "consisting essentially of" and "consisting of." In addition, the present invention includes any combination of the constituent elements described in this specification.

 また、上述した本発明の各実施形態について説明した各種特性(性質、構造、機能等)は、本発明に包含される主題を特定するにあたり、どのように組み合わせられてもよい。すなわち、本発明には、本明細書に記載される組み合わせ可能な各特性のあらゆる組み合わせからなる主題が全て包含される。 Furthermore, the various characteristics (properties, structures, functions, etc.) described for each embodiment of the present invention above may be combined in any way to identify the subject matter encompassed by the present invention. In other words, the present invention encompasses all subject matter consisting of any combination of the combinable characteristics described in this specification.

 以下、本発明を更に詳しく説明するため実施例を挙げる。しかし、本発明はこれら実施例等になんら限定されるものではない。 The following examples are provided to further explain the present invention. However, the present invention is not limited to these examples.

 I.ヒシ抽出物の調製
 収穫後のトウビシ(Trapa bispinosa)の果実を乾燥させ、乾燥果皮を回収した。乾燥果皮を破砕し、熱水抽出(乾燥果皮の1質量部に対し6質量部の90℃の熱水を使用)した。抽出液67質量%に対し33質量%のデキストリンを添加し、スプレードライヤーで噴霧乾燥し、ヒシ果皮抽出粉末を得た。
I. Preparation of water chestnut extract After harvest, the fruits of Trapa bispinosa were dried and dried skin was collected. The dried skin was crushed and extracted with hot water (6 parts by mass of 90°C hot water was used per 1 part by mass of dried skin). 33% by mass of dextrin was added to 67% by mass of the extract, and the mixture was spray-dried with a spray dryer to obtain water chestnut skin extract powder.

 試験食品としてヒシ果皮抽出粉末100mgと賦形剤であるコーンスターチ83.62mg、ステアリン酸カルシウム1.38mgを49mgのハードカプセル封入したカプセル剤(合計質量234mg)を調製した。 The test food was prepared as a capsule (total mass 234 mg) containing 100 mg of water chestnut peel extract powder, 83.62 mg of corn starch as excipients, and 1.38 mg of calcium stearate encapsulated in 49 mg of hard capsules.

 II.プラセボ対照二重盲検ランダム化並行群間試験
 II-1.試験方法
 [被験者]
 本試験の対象者は、健常な40~64歳の日本人男女である。
II. Placebo-controlled, double-blind, randomized, parallel-group study II-1. Study method [Subjects]
The subjects of this study were healthy Japanese men and women aged 40 to 64 years.

 [介入]
 介入期間は8週間とし、試験参加者には試験食品あるいはプラセボ食品を1日1粒朝食前に水又はぬるま湯と共に摂取させた。また、プラセボ食品はヒシ抽出物を含まない賦形剤を用いており、外観、形状、色、におい、味において識別不能であった。
[intervention]
The intervention period was 8 weeks, and participants were instructed to take one tablet of the test food or placebo food per day before breakfast with water or lukewarm water. The placebo food used an excipient that did not contain water chestnut extract, and was indistinguishable in appearance, shape, color, odor, and taste.

 [評価項目]
 ピッツバーグ睡眠質問票(日本語版)による測定を、摂取前、摂取4週間後、摂取8週間後に実施した。
[Evaluation items]
Measurements using the Pittsburgh Sleep Quality Index (Japanese version) were conducted before intake, 4 weeks after intake, and 8 weeks after intake.

 ピッツバーグ睡眠質問票(Pittsburgh.Sleep Quality Index;PSQI)は、総合的な睡眠の質について自記式で回答し採点及び評価を行うことができ、既存の睡眠尺度の中では最も多くのエビデンスが集積されている。ピッツバーグ睡眠質問票は、睡眠の質、入眠時間、睡眠時間、睡眠効率、睡眠困難、睡眠薬の使用、日中の活動障害といった7種類の下位尺度から構成され、それらの合計点で評価を行う。したがって、「広義の意味での睡眠の質(睡眠の総評)」をみるための指標として適切であると考えられている(参考文献:厚生労働省,ピッツバーグ睡眠質問票を指標とし「睡眠の質」と健康アウトカムの関連を検討するシステマティックレビュー,https://mhlw-grants.niph.go.jp/system/files/report_pdf/202009018A-buntan2.pdf) The Pittsburgh Sleep Quality Index (PSQI) allows for self-reporting, scoring and evaluation of overall sleep quality, and is the sleep scale with the most accumulated evidence among existing sleep scales. The Pittsburgh Sleep Quality Index is composed of seven subscales, including sleep quality, time to fall asleep, sleep duration, sleep efficiency, difficulty sleeping, use of sleeping pills and daytime activity disorders, and is evaluated based on the total score of these subscales. Therefore, it is considered appropriate as an index for observing "sleep quality in a broad sense (overall evaluation of sleep)" (Reference: Ministry of Health, Labor and Welfare, Systematic review examining the relationship between "sleep quality" and health outcomes using the Pittsburgh Sleep Quality Index as an index, https://mhlw-grants.niph.go.jp/system/files/report_pdf/202009018A-buntan2.pdf)

 II-2.試験結果
 [群間比較の解析対象者]
 試験に組み入れた56例(試験食品群28例、プラセボ群28例)のうち、4週の測定にのみ来院しなかった1例(試験食品群)、8週の測定にのみ来院しなかった1例(試験食品群)、4及び8週の測定どちらも来院しなかった1例(プラセボ群)が確認された。そのため、試験食品群では4週もしくは8週のどちらかの欠損データを有する被験者を含めた28人を総解析対象人数とし、4週もしくは8週に来院しなかったそれぞれ1例ずつを除外した27例ずつを解析対象データとした。プラセボ群は4及び8週の測定データを取得できなかった1例を除く27例を解析対象者とし、群間比較解析を実施した。
II-2. Study results [Subjects for analysis of intergroup comparison]
Of the 56 subjects enrolled in the study (28 in the test food group and 28 in the placebo group), one subject (test food group) did not visit the hospital for the measurement at week 4 only, one subject (test food group) did not visit the hospital for the measurement at week 8 only, and one subject (placebo group) did not visit the hospital for either the measurement at week 4 or week 8. Therefore, in the test food group, 28 subjects were included in the total number of subjects for analysis, including subjects with missing data at either week 4 or week 8, and 27 subjects each were included in the data for analysis, excluding one subject each who did not visit the hospital at week 4 or week 8. In the placebo group, 27 subjects were included in the analysis, excluding one subject for whom measurement data could not be obtained at weeks 4 and 8, and an intergroup comparison analysis was performed.

 [評価結果 群間比較]
 表1及び図1にピッツバーグ睡眠質問票のスコア及び統計解析結果を示した。摂取4週間後における[C7:日中覚醒困難]のスコアはプラセボ群と比較して試験食品群(TBE(Trapa bispinosa Roxb. Pericarp Extract)群)で有意に低値であり、睡眠の質の改善が確認された。
[Evaluation results: comparison between groups]
The Pittsburgh Sleep Quality Index scores and statistical analysis results are shown in Table 1 and Figure 1. The score of [C7: Difficulty waking during the day] after 4 weeks of intake was significantly lower in the test food group (TBE (Trapa bispinosa Roxb. Pericarp Extract) group) compared to the placebo group, confirming an improvement in sleep quality.

Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001

 [前後比較の解析対象者]
 試験に組み入れた56例(試験食品群28例、プラセボ群28例)のうち、4週の測定にのみ来院しなかった1例(試験食品群)、8週の測定にのみ来院しなかった1例(試験食品群)、4及び8週の測定どちらも来院しなかった1例(プラセボ群)が確認された。そのため、試験食品群は2例を除く26例を解析対象者とし、プラセボ群は1例を除く27例を解析対象者とし、前後比較解析を実施した。
[Subjects for before-and-after comparison analysis]
Of the 56 cases enrolled in the study (28 in the test food group, 28 in the placebo group), one case (test food group) did not visit the hospital for the measurement at week 4, one case (test food group) did not visit the hospital for the measurement at week 8, and one case (placebo group) did not visit the hospital for either the measurements at weeks 4 or 8. Therefore, 26 cases (excluding 2 cases) from the test food group were analyzed, and 27 cases (excluding 1 case) from the placebo group were analyzed, and a before-and-after comparison analysis was performed.

 [評価結果 前後比較]
 表1から、試験食品群において、摂取前と比較して[ピッツバーグ睡眠質問票の総合得点]、[C1:睡眠の質]及び[C7:日中覚醒困難]は摂取4及び8週間後に、[C2:入眠時間]は摂取4週間後に有意に低値を示した。
[Evaluation results before and after comparison]
As shown in Table 1, in the test food group, the Pittsburgh Sleep Quality Index total score, C1: sleep quality, and C7: daytime difficulty waking were significantly lower after 4 and 8 weeks of intake, and C2: time to fall asleep was significantly lower after 4 weeks of intake, compared to before intake.

 [考察]
 ピッツバーグ睡眠質問票は、広くコンセンサスの得られた睡眠の質を評価する評価方法である。試験食品群においてプラセボ群と比較してピッツバーグ睡眠質問票の有意な低下が確認された。試験食品中において健康機能を有する配合成分はヒシ抽出物に限定されることから、ヒシ抽出物の摂取は睡眠の質改善効果を有する可能性が示された。
[Discussion]
The Pittsburgh Sleep Quality Index is a widely accepted method for evaluating sleep quality. A significant decrease in the Pittsburgh Sleep Quality Index was confirmed in the test food group compared to the placebo group. Since the only ingredient in the test food with health benefits was water chestnut extract, it was shown that taking water chestnut extract may have an effect of improving sleep quality.

Claims (5)

 睡眠の質改善剤の製造における、ヒシ属に属する植物又はその処理物の使用。  The use of a plant belonging to the genus Trapa or a processed product thereof in the manufacture of a sleep quality improvement agent.  前記ヒシ属に属する植物がトウビシである、請求項1に記載の使用。 The use according to claim 1, wherein the plant belonging to the genus Trapa is Trapa.  前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の抽出物である、請求項1又は2に記載の使用。 The use according to claim 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of a plant belonging to the genus Trapa.  前記ヒシ属に属する植物又はその処理物が、ヒシ属に属する植物の果皮の抽出物である、請求項1又は2に記載の使用。 The use according to claim 1 or 2, wherein the plant belonging to the genus Trachysperm or a processed product thereof is an extract of the pericarp of a plant belonging to the genus Trachysperm.  前記ヒシ属に属する植物又はその処理物が、トウビシ果皮抽出物である、請求項1又は2に記載の使用。 The use according to claim 1 or 2, wherein the plant belonging to the genus Trapa or a processed product thereof is an extract of Trapa bisporus pericarp.
PCT/JP2024/031944 2023-09-08 2024-09-05 Agent for improving quality of sleep WO2025053239A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-145834 2023-09-08
JP2023145834A JP2025039061A (en) 2023-09-08 2023-09-08 Sleep quality improver

Publications (1)

Publication Number Publication Date
WO2025053239A1 true WO2025053239A1 (en) 2025-03-13

Family

ID=94923304

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/031944 WO2025053239A1 (en) 2023-09-08 2024-09-05 Agent for improving quality of sleep

Country Status (2)

Country Link
JP (1) JP2025039061A (en)
WO (1) WO2025053239A1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094964A (en) * 2008-08-29 2014-05-22 Hayashikane Sangyo Kk Maillard reaction inhibitor
JP2015209420A (en) * 2014-04-30 2015-11-24 林兼産業株式会社 Advanced glycation end products production inhibitor
JP2016145182A (en) * 2015-01-29 2016-08-12 正雄 神野 Improver composition of infertility
JP2018008926A (en) * 2016-06-30 2018-01-18 林兼産業株式会社 Agent for inhibiting production of advanced glycation end product
JP2019052122A (en) * 2017-09-19 2019-04-04 林兼産業株式会社 Adiponectin secretion promoter, adipose precursor cell differentiation promoter, and pharmaceutical composition, food and feed containing them
JP2020029420A (en) * 2018-08-23 2020-02-27 林兼産業株式会社 Composition for hair growth promotion, hair loss prevention or cuticle improvement and wound healing agent
JP2020083815A (en) * 2018-11-26 2020-06-04 林兼産業株式会社 Amyloid β aggregation inhibitor composition, BACE1 inhibitor composition and anti-Alzheimer composition containing them
JP2022067572A (en) * 2020-10-20 2022-05-06 学校法人立命館 5α-REDUCTASE INHIBITOR AND PROSTATIC HYPERPLASIA INHIBITOR

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014094964A (en) * 2008-08-29 2014-05-22 Hayashikane Sangyo Kk Maillard reaction inhibitor
JP2015209420A (en) * 2014-04-30 2015-11-24 林兼産業株式会社 Advanced glycation end products production inhibitor
JP2016145182A (en) * 2015-01-29 2016-08-12 正雄 神野 Improver composition of infertility
JP2018008926A (en) * 2016-06-30 2018-01-18 林兼産業株式会社 Agent for inhibiting production of advanced glycation end product
JP2019052122A (en) * 2017-09-19 2019-04-04 林兼産業株式会社 Adiponectin secretion promoter, adipose precursor cell differentiation promoter, and pharmaceutical composition, food and feed containing them
JP2020029420A (en) * 2018-08-23 2020-02-27 林兼産業株式会社 Composition for hair growth promotion, hair loss prevention or cuticle improvement and wound healing agent
JP2020083815A (en) * 2018-11-26 2020-06-04 林兼産業株式会社 Amyloid β aggregation inhibitor composition, BACE1 inhibitor composition and anti-Alzheimer composition containing them
JP2022067572A (en) * 2020-10-20 2022-05-06 学校法人立命館 5α-REDUCTASE INHIBITOR AND PROSTATIC HYPERPLASIA INHIBITOR

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TOMIYA, Chihiro et al. Impact of Intake of Water Chestnut Pericarp-derived Polyphenols on Voiding-related Quality of Life in Healthy Middle-aged and Older People. Jpn Pharmacol Ther(薬理と治療). 20 December 2023, vol. 51, no. 12, pp. 1835-1845 *
竹下祥子, ヒシエキスのラットを用いた90日間反復経口投与毒性試験, Jpn Pharmacol Ther(薬理と治療), 20 May 2023, vol. 51, no. 5, pp. 633-642, (TAKESHITA, Shoko, A 90-day Repeated Oral Dose Toxicity Study of Water Chestnut Extract in Rats) *

Also Published As

Publication number Publication date
JP2025039061A (en) 2025-03-21

Similar Documents

Publication Publication Date Title
KR20190079202A (en) Fermentation method of lactic acid bacteria using citrus fruit and its use
JP6640392B2 (en) Obesity control composition
JP2017141199A (en) Liver function improving agent
KR102153414B1 (en) Composition for improving hair loss and promoting hair growth containing a fermented soybean
JP5685752B2 (en) Blood flow promoting agent
JP3768795B2 (en) Xanthine oxidase inhibitor
KR101427784B1 (en) An anti-diabetes composition comprising Ginseng Radix and mulberry tree extract as effective ingredients
KR101760512B1 (en) Compositions comprising mixed herbal extracts for preventing, treating or improving chronic inflammatory diseases
KR101468551B1 (en) Composition containing extract of dendropanax morbifera the improvement and remedial of insominia
JP2003055244A (en) Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent
JP5597828B2 (en) Hair restorer
JPWO2004112817A1 (en) Celery family-derived extract and method for producing the same
KR101486484B1 (en) A food composition for the improvement or prevention of asthma comprising extract of allium hookeri
KR101964249B1 (en) Composition for preventing, improving or treating atopic dermatitis comprising mixture of Torilis japonica extract and copper tripeptide-1 as effective component
KR101525877B1 (en) A composition for preventing wrinkle of skin and anti aging of skin
JP7296611B2 (en) Nitric oxide production accelerator
JP7229513B2 (en) Brain function improving agent and food and drink for improving brain function
JP4224593B2 (en) Composition for suppressing fat accumulation comprising wasabi as an active ingredient
KR101910013B1 (en) A composition for improving, preventing and treating of pain comprising herb extract
WO2005094860A1 (en) Agent improving peripheral blood flow
WO2025053239A1 (en) Agent for improving quality of sleep
KR101248378B1 (en) Pharmaceutical composition for arthritis treatment and prevention
JP2010180141A (en) Anti-allergic composition
JP2017165686A (en) Liver function improver
KR20220092745A (en) A composition for stimulating growth of hairs contaning natural complex extracts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24862888

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载